Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Spyre Therapeutics Inc. (SYRE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: SYRE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -73.58% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.08B USD | Price to earnings Ratio - | 1Y Target Price 55.11 |
Price to earnings Ratio - | 1Y Target Price 55.11 | ||
Volume (30-day avg) 677803 | Beta 2.99 | 52 Weeks Range 15.24 - 40.84 | Updated Date 04/1/2025 |
52 Weeks Range 15.24 - 40.84 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.18 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -27.43% | Return on Equity (TTM) -59.28% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 817897066 | Price to Sales(TTM) 650.22 |
Enterprise Value 817897066 | Price to Sales(TTM) 650.22 | ||
Enterprise Value to Revenue 1964.91 | Enterprise Value to EBITDA -7.96 | Shares Outstanding 60257000 | Shares Floating 46615913 |
Shares Outstanding 60257000 | Shares Floating 46615913 | ||
Percent Insiders 8.72 | Percent Institutions 101.11 |
Analyst Ratings
Rating 4.82 | Target Price 58.62 | Buy - | Strong Buy 10 |
Buy - | Strong Buy 10 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Spyre Therapeutics Inc.
Company Overview
History and Background
Spyre Therapeutics, Inc. (formerly Aeglea BioTherapeutics) is a clinical-stage biotechnology company founded in 2013. It focuses on developing antibody therapies for inflammatory bowel disease (IBD). The company has transformed its focus shifting from rare metabolic diseases to immunology.
Core Business Areas
- SPY001 Development: Developing SPY001, an anti-TL1A antibody, for the treatment of ulcerative colitis and Crohnu2019s disease.
- SPY002 Development: Developing SPY002, an anti-integrin u03b1vu03b27 antibody, for the treatment of ulcerative colitis.
- SPY003 Development: Developing SPY003, an anti-CD31 antibody for IBD patients.
Leadership and Structure
Cameron Turtle (CEO), Shih-Lee Chang (Chief Scientific Officer), and a board of directors oversee the company's strategic direction and operations.
Top Products and Market Share
Key Offerings
- SPY001: An anti-TL1A antibody in Phase 1 clinical trials for ulcerative colitis and Crohn's disease. Market share is not yet applicable as it is in clinical trials. Competitors include Prometheus Biosciences (acquired by Merck), Roivant Sciences (Telavant), and others developing TL1A inhibitors.
- SPY002: An anti-integrin u03b1vu03b27 antibody for ulcerative colitis, in preclinical development. Market share is not yet applicable. Competitors include Takeda (Vedolizumab).
- SPY003: An anti-CD31 antibody for IBD patients in preclinical development. Market share is not yet applicable.
Market Dynamics
Industry Overview
The IBD therapeutics market is a large and growing market driven by increasing prevalence and unmet medical needs. It is characterized by innovation and competition, including biologics and small molecule drugs.
Positioning
Spyre is positioned as an innovative company developing novel antibody therapies for IBD with a focus on addressing unmet needs and improving patient outcomes. Focus on targeted therapies to improve efficacy.
Total Addressable Market (TAM)
The IBD market is estimated to be substantial, around $20 billion. Spyre is positioned to capture a portion of this TAM by developing targeted therapies with potentially improved efficacy and safety profiles.
Upturn SWOT Analysis
Strengths
- Novel antibody pipeline targeting key IBD pathways
- Experienced leadership team with expertise in drug development
- Strong intellectual property portfolio
- Focus on precision medicine and biomarker-driven development
Weaknesses
- Clinical-stage company with no currently marketed products
- High risk associated with drug development
- Dependence on successful clinical trial outcomes
- Limited financial resources compared to larger competitors
Opportunities
- Large and growing IBD market with unmet medical needs
- Potential for breakthrough therapies with improved efficacy and safety
- Strategic partnerships and collaborations
- Expansion into new IBD indications
Threats
- Clinical trial failures
- Competition from established players and new entrants
- Regulatory hurdles and delays
- Pricing pressures and reimbursement challenges
Competitors and Market Share
Key Competitors
- MRK
- ROIV
- TAK
Competitive Landscape
Spyre's competitive advantage lies in its novel antibody targets and focus on precision medicine. Disadvantages include its early stage and limited resources.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's early stage. Future growth depends on clinical trial successes.
Future Projections: Future growth projections depend on successful development and commercialization of its pipeline.
Recent Initiatives: Focus on clinical development of SPY001 and advancement of SPY002 and SPY003 programs.
Summary
Spyre Therapeutics is an early-stage biotechnology company focusing on developing antibody therapies for IBD. Its strength is its innovative pipeline. Its clinical trials and competition are potential risks. It has the ability to capture market share if it's clinical trials are a success and it can overcome hurdles.
Similar Companies
- IMVT
- ALPN
- ARQT
Sources and Disclaimers
Data Sources:
- Spyre Therapeutics Inc. SEC Filings, Investor Presentations, Press Releases
- Analyst Reports
- Company Website
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The biotechnology industry is inherently risky, and past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Spyre Therapeutics Inc.
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2016-04-07 | CEO & Director Dr. Cameron Turtle DPHIL, Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 65 | Website https://www.spyre.com |
Full time employees 65 | Website https://www.spyre.com | ||
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.